Ipilimumab et cancer bronchique métastatique: peut-on changer l'histoire naturelle de la maladie ?

Translated title of the contribution: Ipilimumab and metastatic lung cancer: Can we change the natural history of the disease?

A. Boyer, L. Greillier, H. Barazzutti, P. Tomasini, F. Barlesi

Research output: Contribution to journalArticlepeer-review

Abstract

Ipilimumab (anti CTLA-4 antibody) aims to activate antitumor immunity. Thistreatment is being evaluated in non-small cell lung cancer.Case report.-We report a case of a stage IV adenocarcinoma patient randomized in 2008 in thephase II trial CA 184-104 evaluating the combination of ipilimumab to chemotherapy with car-boplatin and paclitaxel. After an initial partial response to chemotherapy, the patient achieveda complete response with ipilimumab as maintenance therapy. However, it was complicatedby grade 3 gastro-intestinal toxicity leading to stop the ipilimumab. However, this completeresponse persists after 6 years.Conclusions.-Our case illustrates the contribution of immunotherapy at least in some patients.The mechanisms of action, relationship between efficacy and toxicity and predictors of efficacyremain to be defined.

Translated title of the contributionIpilimumab and metastatic lung cancer: Can we change the natural history of the disease?
Original languageFrench
Pages (from-to)949-952
Number of pages4
JournalRevue des Maladies Respiratoires
Volume32
Issue number9
DOIs
Publication statusPublished - 1 Nov 2015
Externally publishedYes

Cite this